CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acticor Biotech SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acticor Biotech SA
Hopital Bichat INSERM
U1148, 46, rue Henri Huchard
PARIS, 75018  France Ticker: ALACTALACT
Business Summary
Acticor Biotech SAS is a France-based company. The Company is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board AlainMunoz 75 10/14/2021 10/14/2021
Chief Executive Officer, Director GillesAvenard 73 1/1/2022
Deputy Chief Executive Officer, Chief Scientific Officer SophieLebel-Binay 56 10/14/2021
12 additional Officers and Directors records available in full report.

General Information
Number of Employees: 24 (As of 6/30/2023)
Outstanding Shares: 12,338,781 (As of 6/30/2023)
Stock Exchange: EPA


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024